The crosstalk between NLRP3 inflammasome and gut microbiome in atherosclerosis. (July 2022)

• Record Type: Journal Article
• Authors: Zhang, Xiao-Nan; Yu, Zong-Liang; Chen, Ji-Ye; Li, Xiao-Ya; Wang, Ze-Ping; Wu, Min; Liu, Long-Tao
• Is Part Of: Pharmacological research. Volume 181(2022)
• Publication Date: 2022-07
• Subjects: HFD high-fat-diet -- ox-LDL oxidized low-density lipoprotein -- LDL-C low-density lipoprotein cholesterol -- TC total cholesterol -- TG triglyceride -- HDL-C high-density lipoprotein cholesterol -- Gal-3 galectin-3 -- NLRP3 Nod-like receptor family pyrin domain containing 3 -- IL interleukin -- LEP leptin -- TBARS thiobarbituric acid-reacting substance -- LPS lipopolysaccharide -- ZO-1 zona occludens 1 -- PPAR peroxisome proliferator-activated receptor -- CPT-1 carnitine palmitoyltransferase 1 -- SCFA short chain fatty acid -- TMA trimethylamine -- TMAO trimethylamine-N-oxide -- AMPK adenosine monophosphate (AMP)-activated protein kinase -- MyD88 myeloid differentiation factor 88 -- TLR4 toll-like receptor 4 -- NF-κB nuclear factor κB -- MMP9 matrix metalloproteinase 9 -- TNF tumor necrosis factor -- TGF growth factors like transforming growth factor -- FATP4 fatty acid transport protein 4 -- ApoB apolipoprotein B -- FABP2 fatty acid binding protein 2 -- DGAT diacyl glycerol acyl transferase -- SCD1 stearoyl-coenzyme A desaturase 1 -- SREBP2 sterol regulatory element-binding protein 2 -- BSH bile salt hydrolase -- FXR enterohepatic farnesoid X receptor -- FGF15 fibroblast growth factor 15 -- CYP7A1 cholesterol 7a-hydroxylase -- BA bile acid -- M-CSF macrophage-colony stimulating factor -- ICAM intercellular adhesion molecule -- MCP-1 monocyte chemoattractant protein-1 -- VCAM vascular cellular adhesion molecule -- FMO3 flavin-containing monooxidase-3 -- TCA tauro-cholic acid -- IBABP ileal bile acid binding protein -- ERK1/2 extracellular signal-regulated kinase 1/2 -- TBA total bile acid -- PCSK9 proprotein convertase subtilisin/Kexin type 9 -- IDOL inducible degrader of low-density lipoprotein receptor -- MDA malondialdehyde -- LDH lactate dehydrogenase -- SOD superoxide dismutase -- SREBP1 sterol regulatory element binding protein 1 -- ACC acetyl-CoA carboxylase; Atherosclerosis -- NLRP3 inflammasome -- Gut microbiome -- Mechanism -- Treatment; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2022.106289
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: Atherosclerosis (AS) is chronic pathological process based on the inflammatory reaction associated with factors including vascular endothelial dysfunction, inflammation, and autoimmunity. Inflammasomes are known to be at the core of the inflammatory response. As a pattern recognition receptor of innate immunity, the NLRP3 inflammasome mediates the secretion of inflammatory factors by activating the Caspase-1, which is important for maintaining the immune system and regulating the gut microbiome, and participates in the occurrence and development of AS. The intestinal microecology is composed of a large number of complex structures of gut microbiota and its metabolites, which play an important role in AS. The gut microbiota and its metabolites regulate the activation of the NLRP3 inflammasome. Targeting the NLRP3 inflammasome and regulating intestinal microecology represent a new direction for the treatment of AS. This paper systematically reviews the interaction between the NLRP3 inflammasome and gut microbiome in AS, strategies for targeting the NLRP3 inflammasome and gut microbiome for the treatment of AS, and provides new ideas for the research and development of drugs for the treatment of AS. Graphical Abstract: ga1